{"id":"W3012535443","doi":"10.1038/s41416-020-0774-1","title":"Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours","year":2020,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Astellas Pharma; Imperial Experimental Cancer Medicine Centre; Ono Pharmaceutical; Eisai; National Institute for Health and Care Research; Advanced Accelerator Applications; Daiichi Sankyo Europe; Bayer HealthCare; Sanofi; Exelixis; Astex Pharmaceuticals; Taiho Pharmaceutical; Boehringer Ingelheim; Yuhan; Gilead Sciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pharmacokinetics; Medicine; Pharmacodynamics; Internal medicine; Toxicity; Adverse effect; Dosing; Oncology; Insulin-like growth factor; Pharmacology; Growth factor; Gastroenterology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002807721,0.001696629,0.001692758,0.0003930083,0.0004222388,0.0008862718,0.0007710004,0.001242602,0.00324191],"category_scores_gemma":[0.001593305,0.0006233128,0.00134556,0.0003548908,0.001017574,0.0008708498,0.0004662326,0.003376099,0.0007876753],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001267452,"about_ca_system_score_gemma":0.001225548,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006389713,"about_ca_topic_score_gemma":0.001442872,"domain_scores_codex":[0.9991007,0.0004807783,0.0000546586,0.0001508177,0.00008124194,0.0001318918],"domain_scores_gemma":[0.9985939,0.0003137126,0.0003370421,0.0001755962,0.0001193575,0.0004604193],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5122648,0.1264272,0.007841866,0.00243766,0.001839995,0.0006573085,0.0009823098,0.002389725,0.1850376,0.000661783,0.006822637,0.1526372],"study_design_scores_gemma":[0.2093083,0.7528483,0.009437989,0.00006792043,0.0005763395,0.0007423489,0.00006462768,0.0005293926,0.01708513,0.0002446842,0.009055057,0.00003990065],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874608,0.004486187,0.001295804,0.0003842258,0.0001274376,0.00299565,0.001196786,0.0000830266,0.001969915],"genre_scores_gemma":[0.9828619,0.003293119,0.002316517,0.0007342094,0.0002674836,0.003493165,0.00311118,0.00004832344,0.003874107],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00324191,"threshold_uncertainty_score":0.01484883,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02260560346040347,"score_gpt":0.3198738740015921,"score_spread":0.2972682705411887,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}